Patrick Goldstein

Suggest Changes
Learn More
AIMS In the HORIZONS trial, in-hospital treatment with bivalirudin reduced bleeding and mortality in primary percutaneous coronary intervention (PCI) compared with heparin and routine glycoprotein(More)